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Abstract
Background: The analysis of large-scale gene expression data is a fundamental approach to
functional genomics and the identification of potential drug targets. Results derived from such
studies cannot be trusted unless they are adequately designed and reported. The purpose of this
study is to assess current practices on the reporting of experimental design and statistical analyses
in gene expression-based studies.
Methods: We reviewed hundreds of MEDLINE-indexed papers involving gene expression data
analysis, which were published between 2003 and 2005. These papers were examined on the basis
of their reporting of several factors, such as sample size, statistical power and software availability.
Results: Among the examined papers, we concentrated on 293 papers consisting of applications
and new methodologies. These papers did not report approaches to sample size and statistical
power estimation. Explicit statements on data transformation and descriptions of the normalisation
techniques applied prior to data analyses (e.g. classification) were not reported in 57 (37.5%) and
104 (68.4%) of the methodology papers respectively. With regard to papers presenting biomedical-
relevant applications, 41(29.1 %) of these papers did not report on data normalisation and 83
(58.9%) did not describe the normalisation technique applied. Clustering-based analysis, the t-test
and ANOVA represent the most widely applied techniques in microarray data analysis. But
remarkably, only 5 (3.5%) of the application papers included statements or references to
assumption about variance homogeneity for the application of the t-test and ANOVA. There is still
a need to promote the reporting of software packages applied or their availability.
Conclusion: Recently-published gene expression data analysis studies may lack key information
required for properly assessing their design quality and potential impact. There is a need for more
rigorous reporting of important experimental factors such as statistical power and sample size, as
well as the correct description and justification of statistical methods applied. This paper highlights
the importance of defining a minimum set of information required for reporting on statistical design
and analysis of expression data. By improving practices of statistical analysis reporting, the scientific
community can facilitate quality assurance and peer-review processes, as well as the reproducibility
of results.
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Background
The analysis of large-scale gene expression has become a
fundamental approach to functional genomics, the iden-
tification of clinical diagnostic factors and potential drug
targets. DNA microarray technologies provide exciting
opportunities for analysing the expression levels of thou-
sands of genes simultaneously [1]. A fundamental objec-
tive in microarray data analysis is to identify a subset of
genes that are differentially expressed between different
samples (e.g. conditions, treatments or experimental per-
turbations) of interest. However, despite the exponential
growth of these studies published in journals, relatively
little attention has been paid to the task of reporting
important experimental design and analysis factors. Now-
adays, researchers, clinicians and decision makers rely on
such publications, an implicitly on the peer review proc-
ess, to assess the potential impact of research, reproduce
findings and further develop the research area. Informa-
tion on experimental design and the correct use of statis-
tical methods is fundamental to aid the community in
correctly accomplishing their interpretations and assess-
ments.
Over the past few decades the medical research disci-
plines, especially the area of clinical trials, have widely
emphasised the importance of rigorous experimental
design, statistical analysis implementation and the correct
use of statistics in peer-reviewed publications [2-6].
Although the general understanding of basic statistical
methods (e.g. t-test, ANOVA) has improved in these disci-
plines, some errors regarding their sound application and
reporting can still be found. For instance, the t-test and
ANOVA are fairly robust to moderate departures from its
underlying assumptions of normally-distributed data and
equality of variance (homogeneity) except in the presence
of very small or unequal sample sizes, which can consid-
erably decrease the statistical power of the analyses [7-10].
In order to promote a more rigorous application and
reporting of data analyses in the area of clinical trials, the
Consolidated Standards of Reporting Trials (CONSORT)
have been adopted. CONSORT has significantly assisted
researchers in improving the design, analysis and report-
ing of clinical trials [11]. This is an example of how a com-
munity-driven effort can help to improve the reporting of
scientific information. Moreover, this instrument has
shown to be helpful to authors, reviewers, editors and
publishers to improve the readers' confidence in the scien-
tific quality, relevance and validity of the studies pub-
lished. We and others argue [12,13] that there is still a
need for more rigorous approaches to reporting informa-
tion relevant to gene expression data analysis. Therefore,
it is important to have a closer look at the level achieved
by recently published papers in connection to fundamen-
tal factors for correctly justifying, describing and interpret-
ing data analysis techniques and results.
The main objective of this investigation is to assess the
reporting of experimental design and statistical methodol-
ogies in recently published microarray data analysis stud-
ies. Among the experimental design factors under study
are sample size estimation, statistical power and normali-
sation. This paper also provides insights into the design of
studies based on well-known statistical approaches, such
as t-test and ANOVA. Our research also examined how
papers present fundamental statistical justifications or
assumptions for the correct application of the t-test and
ANOVA, which are widely applied to gene expression data
analysis.
Methods
PubMed [14] was used to identify papers presenting results
on gene expression data analysis between 2003 and 2005
using "gene expression data" as the query expression. A
manual selection process was implemented in which the
following categories of papers were excluded: a) review
articles; b) commentaries and brief communications; and
c) editorial notes including correspondence to editors.
Furthermore, we excluded papers concentrating on: a)
Web servers, b) databases, and c) software tools. Full
papers were then obtained from different journals [see
Additional file 1]. The reporting of the following factors
was examined: a) type of study (two main types: papers
focused on the presentation of new analysis methodologies
and biomedical-relevant applications); b) reporting of
methods of sample size calculation and statistical power;
c) reporting of data standardisation (i.e. normalisation)
and method of normalisation applied; d) description of
data analysis techniques applied; e) discussion about
missing values; f) explicit statement of directionality (i.e.
one-sided or two-sided test); g) explicit statement of
hypothesis and alternative; and h) reference to software
tools applied for implementing data analyses. In this
study application papers refer to any paper whose main
contribution is the generation or testing of biological or
biomedical hypotheses, including potential diagnostic,
prognostic and therapy design applications, as well as bio-
logically-relevant discoveries. Methodology articles
emphasize the presentation of a novel, problem-specific
(experimental or computational) method or procedure,
which may drive a biologically-relevant advancement or
discovery.
In connection to the description of data analysis tech-
niques applied, we concentrated on the assessment of
techniques or models that were fundamental to obtain
key findings in the application and methodology papers.
With regard to the discussion of missing data estimation
methods, we targeted the application of previously-pub-
lished imputation or estimation methods.BMC Medical Informatics and Decision Making 2006, 6:27 http://www.biomedcentral.com/1472-6947/6/27
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We examined the two main categories of papers on the
basis of the factors defined above. For all the factors,
except for factor d), we asked whether or not a factor was
reported in each paper. In relation to factor d), we
reviewed the techniques applied and then organised the
papers into groups according to major data analysis para-
digms or approaches. Table 1 describes the factors
assessed along with key references, which may provide the
reader with further details about these concepts and rele-
vant approaches.
Results
We reviewed papers published in Medline-indexed jour-
nals. Among these papers 152 (51.9%) concentrated on
the presentation of new methodologies for gene expres-
sion data analysis, and 141 (48.1%) papers mainly con-
tributed application studies, e.g. discoveries directly
relevant to molecular biology and clinical studies. The
definition of these paper categories was provided above.
Our results show that none of the 293 applications and
methodology papers reported approaches to sample size
calculation. Moreover, none of these papers reported
information relating to the statistical power of their anal-
yses. Only 23 (7.8%) of the papers (9 application and 14
methodology papers) presented discussions about the
limitations of small sample sizes in their analyses of real
data. Among the methodology papers, only 9 (5.9%)
manuscripts provided evidence that their analyses tech-
niques were adequate (e.g. exhibiting good statistical
power) for small sample sizes. Only 1 of the application
papers discussed statistical power and sample size factors.
Among the methodology papers, 94 (61.8%) used real
data for assessing the data analysis methodologies or tech-
niques proposed. Three of the methodology papers (2%)
only used simulated data to support their evaluations; and
55 (36.2%) papers analysed both real and simulated data
for evaluating the methodologies proposed. Table 2
shows the reporting of normalisation and description of
normalisation techniques for methodology and applica-
tion papers. It indicates a lack of information on normal-
isation procedures applied.
Among the 141 application papers, 11 papers (7.8%) did
not report the statistical methods used in their data anal-
yses. Clustering-based analysis, the t-test and ANOVA rep-
resent the most widely applied techniques in microarray
data analysis studies (Table 3). Table 3 also shows that
from the 141 application papers, 68 papers applied statis-
tical analyses based on the t-test (21 papers) or ANOVA
(47 papers). However, our review showed that only 5
(3.5%) of the application papers discussed variance
homogeneity assumptions in their analyses. Moreover,
only 7 (4.6%) of the methodology papers presented statis-
tical justifications for the application of either ANOVA or
the t-test.
Our results showed that among the methodology and
application papers, 133 (87.5%) and 115 (82%) did not
report the directionality of the tests (one-sided or two-
sided test) respectively. Also among the methodology and
application papers, only 19 (12.5%) and 26 (18%)
included discussions about missing values (report of
missing values, estimation of missing values or descrip-
tion of methods for missing value estimation) respec-
tively. Explicit statements of hypothesis and alternative
hypothesis were reported in only 43 (28%) and 29
(20.6%) methodology and application papers respec-
Table 1: Definition of factors assessed in gene expression data analysis papers.
Factor Brief definition or question of interest Key references*
Sample size Estimation of the number of arrays required in order to identify significantly, 
differentially expressed genes.
[15–26]
Statistical power Ability of a study to detect a true difference between genes, biological category or 
condition
[2,24,27–28]
Normalisation Does the paper report normalisation of data? (yes or no) [29–32]
Normalisation method Does the paper describe how sources of variation were removed or data 
standardisation method, e.g. total intensity normalisation, normalisation using regression 
techniques, normalisation using ratio statistics etc.
[29–32]
Test directionality Explicit statement of directionality of the statistical test applied, i.e. one-sided or two-
sided test
[33–35]
Hypothesis and alternative Explicit statement of null (H0) or alternative hypothesis (H1) [36–39]
Missing values Report of missing values, report of estimation of missing values or description of method 
for estimating missing values.
[40–42]
Software Which software, programs or tools were used for statistical analysis? [43–44]
Analysis technique Which statistical approaches were used for gene expression data analysis? [1,45–47]
Homogeneity of variances Does the paper report the equality of variances assumption for the application of 
ANOVA and t-test?
[48–49]
* Review articles that may be useful to introduce the reader to these concepts and relevant approaches.BMC Medical Informatics and Decision Making 2006, 6:27 http://www.biomedcentral.com/1472-6947/6/27
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tively. In addition, of the 141 application papers, only 52
(36.9%) included sections or sub-sections to describe data
analysis methods applied.
As shown in Table 4, 39 methodology and 46 application
papers did not adequately report the software tools used
to implement their data analyses. Our review found that
among these 85 papers: 53 did not discuss software or
algorithms applied to data analysis at all, and 24 papers
presented incomplete or unclear descriptions of the soft-
ware or algorithms applied (i.e. the reader would not be
able to identify the type of statistical methodology or soft-
ware package applied). Only 8 papers from the methodol-
ogy and application categories offered full software
implementations of the statistical analysis algorithms
applied upon request from the authors. However, 208
papers included information on software tools or algo-
rithms applied. A closer look at these 208 papers reveals
the application of 274 software tools or programs either
implemented by the authors or obtained from other
resources to perform their data analyses. Table 5 shows
the most used software packages, tools or programs. It
indicates an increasing tendency to make software tools
available on the Web. It also highlights the diversity of
standalone and proprietary packages and implementa-
tions applied for data analysis.
Discussion
Our assessment suggests that published papers lack rele-
vant information regarding the determination of sample
sizes and statistical power in microarray data analysis
studies. These studies often involve hundreds or thou-
sands of genes and only a fraction of genes are expected to
be differentially expressed. Therefore, genes that do not
show clear patterns of differential expression are filtered
out, by performing statistical group comparisons. How-
ever, if the subjects or arrays (sample size) have not been
properly estimated before the statistical comparisons (e.g.
ANOVA or t-test) then spurious predictions and type II
errors (β) can be seriously misleading. In fact, undetected
significant differences may be explained by a lack of statis-
tical power for detecting true differences between genes or
as a result of inadequate sample sizes (subjects or arrays).
Our study showed that very few research studies (i.e.
either methodology or application papers) discuss power
and sample size requirements in microarray experiments,
which are fundamental factors to accomplish the valida-
tion of the statistical analyses [15-26].
Our review also shows that although classic ANOVA and
the t-test are widely applied to the analysis of gene expres-
sion data, fundamental statistical assumptions, such as
the homogeneity of variances, are seldom mentioned.
Therefore, even if we ignore the constraints defined by
small sample size in the application of ANOVA and t-test,
these papers fail to justify their application on the basis of
their assumptions of homogeneity of variance. Research-
ers also have the option of implementing other statistical
significance tests that may relax the assumption of homo-
geneity of variance. Researchers should also be aware of
the limitations of the classic t-test and ANOVA methods
for detecting differential expression patterns, e.g. statisti-
cal power and detection of spurious relations. Therefore,
relatively more powerful and reliable alternatives may be
carefully considered, such as distribution-free tests, linear
models with empirical Bayes corrections or other signifi-
cance analysis techniques for gene expression data.
Furthermore, our results indicate that gene expression
data analysis papers should provide additional informa-
tion on data normalisation methods applied. This impor-
tant data analysis reporting task deserves more attention
in order to support a more accurate interpretation and
reproducibility of results. Although previous research [53]
has suggested relatively high robustness of microarray
data analysis to different types of normalisation tech-
niques, more evidence clearly indicates that prediction
outcomes can be significantly affected by the selection of
normalisation methods [29-32]. Therefore, we argue that
authors should not only indicate that their data have been
normalised, but also they should provide details on the
normalisation method applied and assumptions.
Our findings show that only 45 (15.4%) methodology
and application papers explicitly discussed issues relating
missing values, e.g. sources and estimation methods.
Gene expression data often contain missing expression
values, which may require the application of missing data
estimation or imputation techniques to obtain a complete
matrix of expression values. Like in the case of data nor-
malisation, authors not only should report on missing
values, but also on their approaches to dealing with such
a problem. Again this is a crucial factor because different
estimation methods may have different effects on the
same dataset [40-42,54]. Also our results stress the need to
continue encouraging authors to provide adequate
descriptions of the software tools or resources applied to
implement their data analyses. For instance, 53 (18.1%)
of the application and methodology papers examined did
not provide any information on the software package or
programs used to implement their statistical analyses.
Finally, our review suggests that the above reporting prac-
tices may be improved by encouraging authors to provide
separate sections or sub-sections focusing on data analy-
sis. Only 36.9% of the application papers, for example,
included a section dedicated to these aspects, i.e. detailed
discussion of methods, tools, assumptions. A section (or
sub-section) on statistical methods should clearly state,
for instance, how the sample size was estimated and howBMC Medical Informatics and Decision Making 2006, 6:27 http://www.biomedcentral.com/1472-6947/6/27
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the data were analysed in relation to each of the objectives
and underlying biological and statistical assumptions
made. Such a section should also include information
about statistical software or tools applied for data analysis
(e.g. origin and availability) and the directionality of the
statistical tests applied.
Even when this study did not aim to analyse the possible
causes of such relative lack of statistical information
reporting standards, it is necessary to stress the impor-
tance of ensuring the participation of statisticians in both
the design and analysis phases of gene expression studies.
However, in some cases this may be accomplished only if
adequate provisions and decisions are made during the
project formulation and funding assessment phases (i.e.
adequate budget considerations should me made to
achieve such participation). An interpretation of the
results on the reporting of test directionality should also
take into account that for many authors it may be com-
mon practice not to report test directionality as they may
assume that two-sided directionality is the default setting.
However, this assumption should not be used to justify
the lack of more rigorous reporting practices, which are
commonly adopted in other statistics-driven areas, such
as medical sciences, epidemiology and clinical trials.
It is also necessary to recognise that the lack of more rig-
orous reporting standards may be understood in the light
of the technical complexities and constraints presented by
the area of gene expression data analysis. For example,
there is a need for more comprehensive theoretical and
empirical studies about the statistical nature of gene
expression data in order to help researchers to present
deeper discussions on sample size and power analysis. In
relation to these factors, one may also argue that, unlike
the clinical sciences domain, there is a lack of accepted,
comprehensively-validated methods tailored to gene
expression data. Therefore, it is fundamental to promote
deeper investigations and the generation of robust, user-
friendly tools to assist researchers in their approaches to
the discussion of these factors.
More investigations on the application and reporting of
other important experimental procedures, such as sample
pooling prior to hybridization, are required. It has been
shown that pooling may significantly affect the quality of
data analysis [55]. Our review showed that only 13
Table 3: Main types of statistical methods applied in microarray data analysis studies.
Technique Application papers (%)* Methodology papers (%)
t-test 21 (14.89) 11 (7.24)
ANOVA 47 (33.33) 22 (14.47)
Data clustering 56 (39.72) 75 (49.34)
Supervised classification 5 (3.55) 37 (24.34)
Mixed classification models 3 (2.13) 12 (7.89)
Nonparametric tests 11 (7.80) 6 (3.95)
Regression analysis 7 (4.96) 11 (7.24)
Correlation-based analyses 23 (16.31) 4 (2.63)
Fuzzy logic methods 0 (0.00) 4 (2.63)
Fisher-exact tests 5 (3.55) 5 (3.29)
PCA 7 (7.96) 4 (2.63)
Discriminant analysis 4 (2.84) 4 (2.63)
Time series analysis 0 (0.00) 6 (3.95)
Meta analysis 2 (1.42) 1 (0.66)
Other methods 9 (6.63) 22 (14.47)
* Percentages calculated in relation to each paper category separately. For example, in connection to the use of t-test in application papers, the 
table indicates that 21 application papers (out of 141), i.e. 14.89 %, used this technique.
Table 2: Reporting normalisation and techniques implemented in published methodology and application papers
Methodology papers Application papers
Reporting normalisation Description of method of 
normalisation
Reporting normalisation Description of method of 
normalisation
Yes (%) No (%) Yes (%) No (%) Yes (%) No (%) Yes (%) No (%)
95 (62.5) 57 (37.5) 48 (31.6) 104(68.4) 100(70.9) 41(29.1) 58(41.1) 83(58.9)BMC Medical Informatics and Decision Making 2006, 6:27 http://www.biomedcentral.com/1472-6947/6/27
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(8.6%) methodology and 21 (14.9%) application papers
reported pooling procedures in their studies. These figures
are in general consistent with previous estimates of the
number of datasets catalogued in the Gene Expression
Omnibus Database using this procedure [56].
Another fundamental analysis factor that continues
deserving additional investigations is the application and
reporting of P-values adjustments. Our review revealed
that only 15 (10.7%) and 28 (18.4%) of the application
and methodology papers respectively explicitly reported
the P-value adjustment method applied. For instance,
among the 141 application papers, 8 (5.7%) and 7 (5%)
papers reported the use of Bonferroni and Benjamini-
Hochberg adjustment methods respectively. With regard
to the methodology papers (152 in total): 14 (9.2%), 12
(7.9%) and 2 (1.3%) papers reported the application of
Bonferroni, Benjamini-Hochberg and Hochberg adjust-
ment methods respectively. The selection of a suitable
adjustment method depends on the error rate that one
wants to control [55]. For example, for controlling family-
wise error rates (FWER) Bonferroni and Hochberg are rec-
ommended, but for controlling false discovery rates
(FDR) Benjamini-Hochberg may be a more appropriate
choice [55,57-59].
Our study may be complemented by other reviews on the
correct application of evaluation strategies, such as data
sampling and significance interpretation [60]. Additional
studies may be useful to assess more specific data analysis
components, such as cross-validation techniques for esti-
mating predictive performance of supervised classifica-
tion models in medical diagnosis and prognosis. To
further support a deeper understanding on issues relevant
to statistical information reporting, the reader is also
referred to [44,45,55], which review some of the most rep-
resentative approaches to analysing gene expression data
in different biomedical applications.
Future work may involve an analysis of potentially inter-
esting, significant time-dependent trends relating to statis-
tical information reporting. This may allow the scientific
community to assess emergent practices and patterns of
knowledge generation and reporting in gene expression
data analysis.
Conclusion
Medical research disciplines, especially the area of clinical
trials, have placed relatively more emphasis on the report-
ing of experimental design, statistical analysis implemen-
tation and the correct use of statistics in peer-reviewed
publications [2-6] in comparison to the current state in
gene expression data analysis.
The present survey indicates that the quality and coverage
of information regarding experimental design and statisti-
cal analysis in gene expression data-driven studies deserve
to be improved. The reporting of statistical power, sample
Table 5: The most applied software tools
Software systems Usage Frequency
Web-based implementations* 40
R3 1
MATLAB 16
MAS 16
SAS 16
GeneSpring [50] 14
Excel 12
TreeView [51] 12
S-PLUS 9
SPSS 8
Standalone programs implemented in C++ or Java 12
Gene Cluster (Cluster) [51] 10
Significance Analysis of Microarrays (SAM) [52] 6
BioMiner 2
Other proprietary implementations 73
* implemented by authors or originating from related studies
Table 4: Reporting on software tools or programs for data analysis included in Table 3.
Methodological papers Application papers
Y e s  ( % )N o  ( % )Y e s  ( % )N o  ( % )
113 (74.3) 39 (25.7) 95 (67.4) 46 (32.6)BMC Medical Informatics and Decision Making 2006, 6:27 http://www.biomedcentral.com/1472-6947/6/27
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size, normalisation and missing data estimation tech-
niques requires a more rigorous treatment. Poor or
incomplete reports may significantly affect our capacity to
interpret results and assess the relevance and validity of
research studies. Moreover, inadequate reporting of statis-
tical analysis information may increase the likelihood of
publishing spurious associations or predictions. By pay-
ing more attention to these factors authors will be facili-
tating quality assurance and peer-review processes, as well
as the reproducibility of results, which are fundamental
factors for the advancement of scientific and technological
development, policy and decision making.
Community-driven efforts such as the MIAME (Minimum
Information About a Microrray Experiment) protocol [61]
may be useful for motivating or guiding the definition of
a well-defined set of requirements for reporting funda-
mental data analysis and experimental statistical design
factors. This research calls for greater discussions involv-
ing researchers, editors, publishers and decision makers.
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